Fluids and drugs formulated for intravenous infusion may potentially promote the growth of microorganisms that can cause infections. The aim of this study is to test the sterility of sclerosing foam.
Methods
Polidocanol was used for the production of the foam. The Tessari method was used in order to generate the foam. The preparation was carried out both in the operating theater and in an outpatient room. A validation test with microorganisms was also performed.
Results
The measurements showed no evident growth of microorganisms and in the validation tests the foam appeared to even display bacteriostatic and/or bactericide properties.
Conclusions
Sclerosing foam seems to be safe from a microbiological point of view.
ZimmetSE. Sclerotherapy treatment of telangiectasias and varicose veins. Tech Vasc Interv Radiol2003; 6: 116–120.
2.
KendlerMWetzigTSimonJC. Foam sclerotherapy – a possible option in therapy of varicose veins. J Dtsch Dermatol Ges2007; 5: 648–654.
3.
TessariL. Nouvelle technique d'obtention de la scléromousse. Phlebologie2000; 53: 129.
4.
Coleridge SmithP. Foam and liquid sclerotherapy for varicose veins. Phlebology2009; 24: 62–72.
5.
WilsonG. Two cases of infection complicating foam ultrasound guided sclerotherapy (UGS). ANZ J Phlebol2005; 9: 39–40.
6.
Van DeurzenBCeulenRPTellingsSS. Polidocanol concentration and time affect the properties of foam used for sclerotherapy. Dermatol Surg2011; 37: 1448–1455.
7.
De RoosKPGroenLLeendersA. Foam sclerotherapy: investigating the need for sterile air. Dermatol Surg2011; 37: 1119–1124.
8.
ISPESL: Istituto Superiore per la Prevenzione e la Sicurezza del Lavoro. Linee guida per la definizione degli standard di sicurezza e di igiene ambientale dei reparti operatori, http://www.ispesl.it/documentazione/comp_sett.asp (2009, accessed January 2012).
9.
European Pharmacopoeia 5.0, Biological test, §2.6.1 Sterility, 2005.
10.
Code of Federal Regulations. Title 21 Food and Drugs, Part 610.12 Sterility testing, Washington, DC: US Government Printing Office, 2012.
11.
AngelilloIFBiancoANobileCGA. Evaluation of the efficacy of glutaraldehyde and peroxygen for disinfection of dental instruments. Lett Appl Microbiol1998; 27: 292–296.
12.
SoncinSLo CiceroVAstoriG. A practical approach for the validation of sterility, endotoxin and potency testing of bone marrow mononucleated cells used in cardiac regeneration in compliance with good manufacturing practice. J Transl Med2009; 7: 78.
13.
RathbunSNorrisAStonerJ. Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders. Phlebology2012; 27: 105–117.
14.
RathbunSNorrisAMorrisonN. Performance of endovenous foam sclerotherapy in the USA for the treatment of venous disorders: ACP/SVM/AVF/SIR quality improvement guidelines. Phlebology2014; 29: 76–82.
15.
CurranE. Intravenous drug preparation: the infection risks. Br J Nurs2011; 20(S4): S6–8.
16.
RickardCMVannapraseuthBMcGrailMR. The relationship between intravenous infusate colonisation and fluid container hang time. J Clin Nurs2009; 18: 3022–3028.
17.
MercaldiCJLanesSBradtJ. Comparative risk of bloodstream infection in hospitalized patients receiving intravenous medication by open, point-of-care, or closed delivery systems. Am J Health Syst Pharm2013; 70: 957–965.
18.
MaciasAEHuertasMde LeonSP. Contamination of intravenous fluids: a continuing cause of hospital bacteremia. Am J Infect Control2010; 38: 217–221.
19.
Hamel-DesnosCOuvryPBenigniJP. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. “The 3/1 Study.”. Eur J Vasc Endovasc Surg2007; 34: 723–729.
20.
GobinJPBenigniJB. Sterivein: un nouveau procédé de fabrication de mousse sclerosante. Phlébologie2006; 59: 73–76.
21.
SehulsterLChinnRY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep2003; 52: 1–42.
